Thus, TOM1L1 is an important element of an ERBB2-driven proteolytic invasive programme and TOM1L1 amplification potentially enhances the metastatic progression of ERBB2-positive breast cancers. This evidence concerns the gene ERBB2 and breast carcinoma.